Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma-Reference-Cited by-同舟云学术

Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma

Published:2015-09 Issue:8 Volume:26 Page:907-909
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Katzel Jed A.,Lee-Ma Annette,Vesole David H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference15 articles.

1. . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.;Druker;N Engl J Med,2006

2. . International randomized study of interferon vs. ST1571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib abstract.;Deininger;Blood,2009

3. . Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.;Kantarjian;Blood,2012

4. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.;Huang;Cancer,2012

5. . Prognostic discrimination in good-risk chronic granulocytic leukemia.;Sokal;Blood,1984

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma in a patient with chronic myeloid leukemia: A case report;Oncology Letters;2023-04-20

2. Coexistence of multiple myeloma and chronic myeloleukosis in one patient;Russian journal of hematology and transfusiology;2020-12-10

3. Imatinib;Reactions Weekly;2015-11